• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Healthcare Quality Institute
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24814 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2009     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Tocolysis in preterm labour - a systematic review of evidence-based guidelines, effectiveness and health economic evaluations
2018     National Institute for Health and Care Excellence (NICE) Tocilizumab for treating giant cell arteritis. NICE technology appraisal guidance 518
2011     National Institute for Health and Care Excellence (NICE) Tocilizumab for the treatment of systemic juvenile idiopathic arthritis. NICE technology appraisal guidance 238
2011     NIHR Health Technology Assessment programme Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
2012     National Institute for Health and Care Excellence (NICE) Tocilizumab for the treatment of rheumatoid arthritis. NICE technology appraisal guidance 247
2009     NIHR Health Technology Assessment programme Tocilizumab for the treatment of rheumatoid arthritis
2021     European Network for Health Technology Assessment (EUnetHTA) Tocilizumab for the treatment of COVID-19
2010     Institute for Clinical Effectiveness and Health Policy (IECS) Tocilizumab for rheumatoid arthritis
2014     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tocilizumab (RoActemra®)
2014     NIHR Horizon Scanning Centre (NIHR HSC) Tocilizumab (RoACTEMRA) for giant cell arteritis – first and second line
2011     NIHR Horizon Scanning Centre (NIHR HSC) Tocilizumab (RoACTEMRA) for early rheumatoid arthritis not treated with methotrexate – first line
2011     NIHR Horizon Scanning Centre (NIHR HSC) Tocilizumab (RoACTEMRA) for early rheumatoid arthritis not treated with methotrexate – first line
2012     NIHR Horizon Scanning Centre (NIHR HSC) Tocilizumab (RoActemra) for active polyarticular juvenile idiopathic arthritis – second line
2006     NIHR Horizon Scanning Centre (NIHR HSC) Tocilizumab (actemra) for rheumatoid arthritis and juvenile idiopathic arthritis: horizon scanning review
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Tocilizumab (Actemra - Hoffmann-La Roche Limited) new indication: polyarticular juvenile idiopathic arthritis
2010     NIHR Horizon Scanning Centre (NIHR HSC) Tobramycin inhaled powder (TIP) for Pseudomonas aeruginosa infection in cystic fibrosis
2015     Institute for Clinical Effectiveness and Health Policy (IECS) Tobramycin inhalation powder versus Tobramycin inhalation solution for cystic fibrosis
2006     Agency for Healthcare Research and Quality (AHRQ) Tobacco use: prevention, cessation, and control
2002     The Swedish Council on Health Technology Assessment (SBU) Tobacco smoking and oral health
2003     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) Tobacco control: a review of the strategies
1999     TNO To the infrastructure of efficient information over medical devices
2006     Norwegian Knowledge Centre for the Health Services (NOKC) TNF-inhibitors in rheumatoid diseases
2001     Blue Cross Blue Shield Association (BCBS) TMR as an adjunct to CABG surgery for the treatment of coronary artery disease
2013     NIHR Horizon Scanning Centre (NIHR HSC) TK cell therapy for acute leukaemia patients who are candidate to haematopoietic stem cell transplantation – adjunct therapy
2023     National Institute for Health and Care Excellence (NICE) Tixagevimab plus cilgavimab for preventing COVID-19. NICE technology appraisal guidance 900
2018     National Institute for Health and Care Excellence (NICE) Tivozanib for treating advanced renal cell carcinoma. NICE technology appraisal guidance 512
2011     NIHR Horizon Scanning Centre (NIHR HSC) Tivozanib for renal cell cancer, locally advanced or metastatic - first line
2011     HAYES, Inc. title
2012     Malaysian Health Technology Assessment (MaHTAS) Titanium dioxide photocatalyst coatings
2005     Institute for Clinical Systems Improvement (ICSI) Tissue-type plasminogen activator for acute ischemic stroke
2007     National Institute for Health and Care Excellence (NICE) Tissue-cultured limbal stem cell allograft transplantation for regrowth of corneal epithelium. NICE interventional procedures guidance 216
2015     HAYES, Inc. Tissue of Origin Test (ResponseDX)
2002     NIHR Horizon Scanning Centre (NIHR HSC) Tissue engineered heart valves - horizon scanning review
2008     HAYES, Inc. Tissue doppler imaging for cardiomyopathy
2008     HAYES, Inc. Tisseel VH (Baxter Healthcare Corp.) for noncardiac surgeries with problematic hemostasis
2008     HAYES, Inc. Tisseel VH (Baxter Healthcare Corp.) for cardiac surgery
2025     National Institute for Health and Care Excellence (NICE) Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 1058
2025     National Institute for Health and Care Excellence (NICE) Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 1068
2025     National Institute for Health and Care Excellence (NICE) Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 1072
2019     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies. NICE technology appraisal guidance 567
2023     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal). NICE technology appraisal guidance 933
2018     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. NICE technology appraisal guidance 554
2024     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under. NICE technology appraisal guidance 975
2022     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal). NICE technology appraisal guidance 842
2024     Agency for Care Effectiveness (ACE) Tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2024     Agency for Care Effectiveness (ACE) Tisagenlecleucel for relapsed or refractory B-cell acute lymphoblastic leukaemia
2019     Canadian Agency for Drugs and Technologies in Health (CADTH) Tisagenlecleucel for acute lymphoblastic leukemia and diffuse large b-cell lymphoma: clinical report
2022     Institute for Clinical and Economic Review (ICER) Tirzepatide for type 2 diabetes
2023     National Institute for Health and Care Excellence (NICE) Tirzepatide for treating type 2 diabetes. NICE technology appraisal guidance 924
2024     National Institute for Health and Care Excellence (NICE) Tirzepatide for managing overweight and obesity. NICE technology appraisal guidance 1026
2002     NIHR Horizon Scanning Centre (NIHR HSC) Tirapazamine for non-small cell lung cancer - horizon scanning review
2010     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tipranavir (Aptivus®) oral solution
2010     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tipranavir (Aptivus®) capsules
2007     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tipranavir (Aptivus®)
2019     Penn Medicine Center for Evidence-based Practice (CEP) Tip positioning of short-term central venous catheters
2002     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Tiotropium: a potential replacement for ipratropium in patients with COPD
2009     Belgian Health Care Knowledge Centre (KCE) Tiotropium in the treatment of chronic obstructive pulmonary disease: health technology assessment
2009     Belgian Health Care Knowledge Centre (KCE) Tiotropium in the treatment of chronic obstructive pulmonary disease health technology assessment
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Tiotropium for moderate-to-severe chronic obstructive pulmonary disease: a review of the clinical effectiveness and cost-effectiveness
2001     NIHR Horizon Scanning Centre (NIHR HSC) Tiotropium for COPD - horizon scanning review
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness
2012     Canadian Agency for Drugs and Technologies in Health (CADTH) Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Tiotropium bromide
2002     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Tiotropium bromide
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Tinzaparin versus dalteparin or enoxaparin for the treatment of venous thromboembolism in adults: safety and guidelines
2015     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tinzaparin sodium (Innohep®)
2010     Canadian Agency for Drugs and Technologies in Health (CADTH) Tinnitus retraining therapy: a review of the clinical effectiveness
1998     Wessex Institute for Health Research and Development (WIHRD) Tinnitus retraining therapy
2004     Washington State Department of Labor and Industries (WSDLI) Tinnitus retraining therapy
2004     WorkSafeBC Tinnitus retraining therapy
2022     WorkSafeBC Tinnitus and the COVID-19 vaccine
1999     Alberta Heritage Foundation for Medical Research (AHFMR) Tin-117m DTPA
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Timothy grass standardized allergenic extract (Grastek — Merck Canada Inc.) indication: allergic rhinitis (grass pollen)
2019     Penn Medicine Center for Evidence-based Practice (CEP) Timing of valve replacement for patients with infective endocarditis and intracranial embolism
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Timing of umbilical cord clamping for neonatal and maternal outcomes
2017     NIHR Health Technology Assessment programme Timing of surgical intervention for developmental dysplasia of the hip: a randomised controlled trial (Hip 'Op)
2024     NIHR Health Technology Assessment programme Timing of Stoma Closure in Neonates: the ToSCiN mixed-methods study
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Timing of enoxaparin administration for the prophylaxis of venous thromboembolism: clinical evidence and guidelines
2026     NIHR Health Technology Assessment programme Timing of birth to improve outcomes in chronic or gestational hypertension: the WILL RCT
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Timing of antibiotic therapy for neisseria gonorrhoeae infection
2008     NIHR Health Technology Assessment programme Time to full publication of studies of anti-cancer medicines for breast cancer, and the potential for publication bias: a short systematic review
2008     NIHR Health Technology Assessment programme Time to full publication of studies of anti-cancer medicines for breast cancer, and the potential for publication bias: a short systematic review
2001     Centre for Clinical Effectiveness (CCE) Time to commencement of oral feeding following laryngectomy
2019     National Institute for Health and Care Excellence (NICE) Tildrakizumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 575
2015     NIHR Horizon Scanning Centre (NIHR HSC) Tildrakizumab for moderate to severe plaque psoriasis
2007     Institute for Clinical Effectiveness and Health Policy (IECS) Tigecycline: usefulness of its clinical application
2011     National Institute for Health and Care Excellence (NICE) Ticagrelor for the treatment of acute coronary syndromes. NICE technology appraisal guidance 236
2011     NIHR Health Technology Assessment programme Ticagrelor for the treatment of acute coronary syndromes
2019     Agency for Care Effectiveness (ACE) Ticagrelor for preventing thrombotic events in adults with acute coronary syndromes
2016     National Institute for Health and Care Excellence (NICE) Ticagrelor for preventing atherothrombotic events after myocardial infarction. NICE technology appraisal guidance 420
2013     NIHR Horizon Scanning Centre (NIHR HSC) Ticagrelor (Brilique) for secondary prevention of cardiovascular disease events in patients with prior myocardial infarction
2015     NIHR Horizon Scanning Centre (NIHR HSC) Ticagrelor (Brilique) for preventing thombotic events in patients with acute ischaemic stroke or high risk transient ischaemic attack
2008     NIHR Horizon Scanning Centre (NIHR HSC) Ticagrelor (AZD6140) for acute coronary syndrome
1992     Health Services Utilization and Research Commission (HSURC) Thyroid testing
2012     HAYES, Inc. Thyroid hormone receptor beta (THRB) gene testing in resistance to thyroid hormone (RTH)
2022     Swiss Federal Office of Public Health (FOPH) Thyroid function tests for the diagnosis of suspected primary or secondary thyroid dysfunction
2008     HAYES, Inc. Thymus transplantation for treatment of children with DiGeorge syndrome
2014     NIHR Horizon Scanning Centre (NIHR HSC) Thymosin beta-4 for epidermolysis bullosa
2012     NIHR Horizon Scanning Centre (NIHR HSC) Thymosin beta-4 for dry eye syndrome
2000     University HealthSystem Consortium (UHC) Thymosin alpha-1